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Abstract
The genetic aetiology of congenital hypopituitarism (CH) is not entirely elucidated.
FGFR1 and PROKR2 loss-of-function mutations are classically involved in hypogonadotrophic
hypogonadism (HH), however, due to the clinical and genetic overlap of HH and CH; these
genes may also be involved in the pathogenesis of CH. Using a candidate gene approach,
we screened 156 Brazilian patients with combined pituitary hormone deficiencies (CPHD)
for loss-of-function mutations in FGFR1 and PROKR2. We identified three FGFR1 variants
(p.Arg448Trp, p.Ser107Leu and p.Pro772Ser) in four unrelated patients (two males) and two
PROKR2 variants (p.Arg85Cys and p.Arg248Glu) in two unrelated female patients. Five of the
six patients harbouring the variants had a first-degree relative that was an unaffected carrier
of it. Results of functional studies indicated that the new FGFR1 variant p.Arg448Trp is a loss-
of-function variant, while p.Ser107Leu and p.Pro772Ser present signalling activity similar to
the wild-type form. Regarding PROKR2 variants, results from previous functional studies
indicated that p.Arg85Cys moderately compromises receptor signalling through both MAPK
and Ca2C pathways while p.Arg248Glu decreases calcium mobilization but has normal MAPK
activity. The presence of loss-of-function variants of FGFR1 and PROKR2 in our patients with
CPHD is indicative of an adjuvant and/or modifier effect of these rare variants on the
phenotype. The presence of the same variants in unaffected relatives implies that they
cannot solely cause the phenotype. Other associated genetic and/or environmental
modifiers may play a role in the aetiology of this condition.
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Introduction
Combined pituitary hormone deficiencies (CPHD) are
defined as the deficiency of two or more pituitary
hormones. They can be associated with complex pheno-
types such as cranial/facial midline defects and other
extra-pituitary features. Mutations in transcription factors
such as PROP1, POU1F1, GLI2, HESX1, LHX3, LHX4, SOX2,
SOX3 andOTX2 underlie CPHD (1, 2). There is clinical and
genetic overlap between CPHD and isolated hypogonado-
trophic hypogonadism (IHH) and/or Kallmann syndrome
(KS), such as midline cerebral and facial defects (3). The
adenohypophyseal and olfactory placodes share a com-
mon embryological origin as they both emerge from the
preplacodal field, which could explain this overlap (4).
FGFR1, a tyrosine kinase receptor, is expressed in
Rathke’s pouch and ventral diencephalon in the develop-
ing human embryo (5). PROKR2 is a G protein-coupled
receptor essential for normal olfactory bulb development
and sexual maturation in mice (6), and it is also involved
in angiogenesis and neuronal migration (7).
Loss-of-function mutations in FGFR1 and PROKR2 are
classically associated with IHH and/or KS (8, 9, 10, 11, 12).
Furthermore, mutations in FGFR1, PROKR2 and FGF8,
the FGFR1 ligand, have already been found to be associated
with hypothalamus–pituitary dysfunction (3, 5, 13).
Our aim was to screen a large cohort of Brazilian
patients with CPHD for loss-of-function mutations in
FGFR1 and PROKR2 to investigate the role of these genes
in the aetiology of hypopituitarism.
Subjects and methods
Selection of patients
We studied 156 Brazilian patients with CPHD recruited
consecutively from the Hospital das Clinicas, University of
Sao Paulo Medical School after approval of the ethical
committee. In addition, informed written consent was
obtained from patients and/or parents. The clinical and
radiological features of this cohort are detailed in
Supplementary Table 1, see section on supplementary
data given at the end of this article.
The diagnosis of CPHD was based on the failure to have
a normal response to a combined pituitary stimulation test
(0.05–0.1 U/kg insulin, 200 mg thyrotrophin-releasing hor-
mone and 100 mg gonadotrophin-releasing hormone, i.v.)
and/or low basal insulin-like growth factor 1 (IGF1), IGF-
binding protein 3, free thyroxine, luteinizing hormone
(LH), follicle-stimulating hormone (FSH), oestradiol or
testosterone and cortisol levels. Height was measured with
a stadiometer, and height standard deviation was calcu-
lated using British references (14). Magnetic resonance
imaging (MRI) scans were performed in a 1.5 Tesla unit
(Sigma; GE, Milwaukee, WI, USA) using T1- and T2-
weighted sagittal and coronal scans. The control group
consisted of 400 healthy Brazilian adults.
Genetic analyses
Genomic DNA was extracted from peripheral blood
leucocytes by standard techniques. The entire coding
region and exon–intron junctions of the FGFR1
(ENST00000341462) and PROKR2 (ENST00000217270)
genes were amplified by PCR and sequenced, using
primers and conditions described previously (8, 12). All
mutations were confirmed in two separate PCR. The
variants in DNA and protein sequences are presented
according to HGSV nomenclature recommendations
(www.hgvs.org/). Mutations in GLI2, LHX4, HESX1,
OTX2 and SOX3 were searched for in the patients
harbouring FGFR1 and PROKR2 variants.
In silico analysis
Computational analysis using algorithms from web-based
tools such as Mutation Taster (http://www.mutationtaster.
org/), SIFT (http://sift.jcvi.org/) and Polyphen-2 (http://
genetics.bwh.harvard.edu/pph2/) was performed for pre-
diction of the pathological effects of the substitutions on
protein sequence.
Functional studies
Luciferase reporter assays " Signalling activity of
FGFR1 mutants was assessed using L6 myoblast cells as
described previously (15). In brief, cells were transiently
transfected with WT or altered FGFR1c expression vector
in combination with the osteocalcin FGF response
element luciferase reporter. Cells were treated with
increasing doses of FGF2 and assayed for luciferase
activity. The data were plotted and fitted with three-
parameter sigmoidal dose–response curves using Prism
Software (version 5; GraphPad, La Jolla, CA, USA).
Transfection experiments were performed in triplicate
and repeated three times. Results of individual experi-
ments were expressed as percentages of the WT value, and
the calculated mean maximal activity (top of the curve)
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from three independent experiments was compared using
Prisms’ F-test function.
Receptor expression and maturation studies "
Endoglycosidase and western analysis were performed as
described previously (15). In brief, COS-7 cells were
transiently transfected with Myc-tagged WT or mutated
FGFR1 cDNA. Samples of cleared cell lysate (4 ml, approxi-
mately 5 mg of total protein) were subjected to PNGasef
and EndoH digestion (New England Biolabs, Ipswich, MA,
USA), resolved on NuPAGE 3–8% Tris–acetate gels (Invi-
trogen) and then subjected to western analysis using an
anti-Myc primary antibody (clone 4A6, 1:2000; Upstate
Biotechnology, Inc., Lake Placid, NY, USA) and a goat anti-
mouse HRP-conjugated secondary antibody (1:20 000;
Upstate Biotechnology, Inc.). To control for equal loading,
blots were stripped and reprobed with HRP-conjugated
anti-b-actin antibody (1:20 000; Abcam, Cambridge, UK).
FGFR1 and b-actin immunoreactivity was quantified by
densitometry of film (BioMAx, Kodak) acquired images
using ImageJ Software (Bethesda, MD, USA). Overall
expression levels of WT and mutant receptors were
determined from the PNGase-treated samples and were
normalized to their respective b-actin levels. Results were
expressed as the ratio between mutant and WT levels. For
receptor maturation studies, the upper (mature) and lower
(immature) band densities were determined individually
from the EndoH-treated samples, and the percentage of
the mature fraction was calculated and expressed as a ratio
of mutant to WT expression. Experiments were repeated
three times, and protein expression and maturation levels
were compared between mutant and WT proteins using
Student’s t-test. Data are presented as the meanGS.E.M.
Cell surface expression " Expression of WT or mutant
FGFR1 at the cell surface was quantified using COS-7 cells
and an antibody binding assay (15). Experiments were
performed in quadruplicate and repeated four times.
Specific cell-surface expression of altered FGFR1 proteins
was compared with that of the WT protein using Student’s
t-test. Data are presented as the meanGS.E.M.
Results
Genetic analyses
We searched for variants in GLI2, LHX4, HESX1, OTX2 and
SOX3 genes in the patients harbouring FGFR1 and PROKR2
variants. These genes are known to be involved in CPHD
and no pathological mutations were found.
FGFR1 " Three missense variants, p.Ser107Leu,
p.Arg448Trp and p.Pro772Ser, were identified in a
heterozygous state in four unrelated patients (two
males), the children of non-consanguineous parents
(Table 1). Results of in silico analysis indicated that
p.Arg448Trp is deleterious according to the Mutation
Taster, SIFT and Polyphen-2 tools, whereas p.Ser107Leu
and p.Pro772Ser were predicted to be disease-causing only
by the Mutation Taster tool.
PROKR2 " Two missense variants, p.Arg85Cys and
p.Arg248Glu, were found in a heterozygous state in two
unrelated females, the children of non-consanguineous
parents (Table 1). Results of in silico analysis indicated that
p.Arg85Cys is damaging according to Mutation Taster,
SIFT and Polyphen-2 whereas p.Arg248Glu was predicted
to be benign using the three in silico prediction tools.
All the five variants have been detected previously in
patients with congenital HH (9, 16, 17). The FGFR1
p.Pro772Ser variant was found in five out of 400 (1.25%)
Brazilian healthy controls, and the PROKR2 variant
p.Arg85Cys was found in one out of 400 (0.25%). The other
threevariantswerenot identified inBrazilianhealthycontrols.
Regarding population genetics, the FGFR1 variant
p.Ser107Leu has a minor allele frequency (MAF) of 0.6%
Table 1 Genotypes and functional in silico prediction of FGFR1 and PROKR2 variants found in patients.
Patient Gene
Nucleotide
change Protein change Functional domain
In silico prediction tools
Mutation Taster SIFT Polyphen-2
I FGFR1 c.320COT p.Ser107Leu Ig-like C2-type 1 domain Disease-causing Tolerated Benign
II FGFR1 c.1342COT p.Arg448Trp Juxta-membrane domain Disease-causing Affects protein
function
Probably
damaging
III FGFR1 c.2314COT p.Pro772Ser C-terminal tail Disease-causing Tolerated Benign
IV FGFR1 c.2314COT p.Pro772Ser C-terminal tail Disease-causing Tolerated Benign
V PROKR2 c.253COT p.Arg85Cys First intracellular loop Disease-causing Affects protein
function
Probably
damaging
VI PROKR2 c.743GOA p.Arg248Glu Third intracellular loop Polymorphism Tolerated Benign
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considering all populations (ALL) of the 1000GENOMES
project. Since the patient was born to Japanese parents, it is
important to consider the MAF in the Japanese population,
which is 2.8%. The FGFR1 variant p.Pro772Ser has a MAF
of 0.5% (ALL 1000GENOMES) and a MAF of 4.2% in
African-American population of the Exome Sequencing
Project (ESP6500). To date, the FGFR1 variant p.Arg448Trp
has not been described in population databases.
The PROKR2 variant p.Arg85Cys has been described in
the databases of the 1000GENOMES project (MAFZ0.2%
ALL) and the ESP6500 project (MAFZ0.6%) in the African-
American population. The PROKR2 variant p.Arg248Glu
has no MAF described in databases. Phenotypes of patients
carrying the variants are detailed in Table 2.
Patients with FGFR1 variants
p.Ser107Leu variant " The FGFR1 variant p.Ser107Leu
was identified in a female patient born to non-consangui-
neous Japanese parents (patient I; Table 2). At first
presentation, she was 15.5 years old and had severe short
stature (K7.6 S.D.), primary amenorrhoea and delayed
bone age (10 years). Endocrine evaluation revealed growth
hormone (GH) and LH/FSH deficiencies. She was treated
for both deficiencies, gained 15.7 cm and attained a final
height of 131.7 cm. Neuroimaging showed a small
anterior pituitary, normal stalk and ectopic posterior
pituitary. Her father was unavailable for genetic study
and her mother was not a carrier of the variant, but her
unaffected sister is a carrier of the same variant.
p.Arg448Trp variant " The p.Arg448Trp variant was
identified in a 4-year-old girl at first presentation (patient II;
Table 2). She was born to non-consanguineous parents,
and there was no history of short stature in her family.
The initial complaint was severe short stature (K3.0 S.D.),
and endocrine evaluation showed GH and thyroid-stimu-
lating hormone (TSH) deficiencies. Both conditions were
treated with good response and the patient achieved the
family target height percentile. She had no pubertal signs
until 13 years of age, and then puberty was induced with
conjugated oestrogens. MRI revealed a small anterior
pituitary, absent stalk and ectopic posterior pituitary. Her
unaffected father and sister are carriers of the same variant.
p.Pro772Ser variant " We identified the FGFR1 variant
p.Pro772Ser in heterozygous state in two unrelated patients.
The first patient (patient III; Table 1) had a history of breech
presentation with forceps delivery. He first presented at age
16 years and 9 months with severe short stature (K6.7 S.D.)
and lack of sexual development with penile length of 4.5!
1.9 cm (!K2.5 S.D.), right testes 1.8!1.0 cm and left testes
1.4!0.9 cm. He had GH, TSH, adrenocorticotrophic hor-
mone (ACTH), LH and FSH deficiencies at laboratory
evaluation. He was treated for all deficiencies and achieved
a final height of 172.5 cm after 6 years of GH treatment. His
unaffected mother is a carrier of the same variant.
The second patient harbouring this variant (patient IV;
Table 1) was born at home without health assistance to
non-consanguineous parents. At first presentation he was
15 years and 2 months old. The main complaints were
short stature (K3.5 S.D.) and lack of sexual development,
with penile length 4.5!1.5 cm (!K2.5 S.D.), the left testis
was retractable and the right testis was 2.8!1.5 cm.
Endocrine tests confirmed GH, TSH, LH and FSH defici-
encies. He was treated for all deficiencies, and GH
treatment was carried out for 3.5 years with growth to a
final height of 172 cm. At adulthood, he developed
obesity class 3 and type 2 diabetes mellitus. His mother
is not a carrier of the variant and his father was not
available for testing.
Table 2 Phenotypes of patients with FGFR1 and PROKR2 variants.
Patient Gene Sex
Age at
diagnosis (years) Hormonal deficiencies MRI
Smell
test Other features
I FGFR1 F 15 GH, LH and FSH APH, EPP, normal stalk NL Japanese ancestry
II FGFR1 F 4 GH, TSH, LH and FSH APH, EPP, absent stalk NL
III FGFR1 M 16 GH, TSH, ACTH, LH and FSH APH, EPP, thin stalk NL Micropenis
IV FGFR1 M 15 GH, TSH, LH and FSH APH, EPP, absent stalk NL Micropenis
V PROKR2 F 19 GH, ACTH, LH and FSH NAP, APP absent stalk NL Diabetes insipidus
VI PROKR2 F 10 GH, TSH, partial ACTH, LH
and FSH
APH, EPP, absent stalk NL Diabetes mellitus,
facial asymmetry and
clinodactyly
F, female; M, male; APH, anterior pituitary hypoplasia; EPP, ectopic posterior pituitary; NAP, normal anterior pituitary; APP, absent posterior pituitary;
NL, normal test.
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Patients with PROKR2 variants
p.Arg85Cys variant " The p.Arg85Cys variant was
identified in a 19-year-old female eunuchoid patient who
presented with primary amenorrhoea and no breast
development (patient V; Table 2). She was born to
non-consanguineous parents. Endocrine tests revealed
GH, ACTH, LH and FSH deficiencies. She also developed
diabetes insipidus 8 years after the diagnosis of hypo-
pituitarism. Neuroimaging revealed a normal anterior
pituitary, absent stalk and a non-visualized posterior
pituitary. Intriguingly, this patient reached normal final
height (168.3 cm) without GH treatment. Her unaffected
father carries the same variant.
p.Arg248Glu variant " The female patient with
p.Arg248Glu variant first presented at 10 years of age
with severe short stature (K5.0 S.D.; patient VI; Table 2). She
was born to non-consanguineous parents at 32 gestational
weeks by Caesarean section due to premature membrane
rupture. Endocrine evaluation detected GH, TSH, LH, FSH
and partial ACTH deficiencies. MRI revealed a small
anterior pituitary, absent stalk and ectopic posterior
pituitary. She has some dysmorphic features such as facial
asymmetry and clinodactyly. She was treated for 8 years,
until 18 years of age, for all deficiencies including GH and
achieved a final height of 166.5 cm. At 24 years old, she
presented with diabetes mellitus and mild elevation of
hepatic enzymes with negative serological test results for
hepatitis and negative test results for autoimmune
diabetes. Her unaffected mother carries the same variant.
Her father died from alcoholic hepatic cirrhosis and had
diabetes mellitus along with her brother and several uncles.
All the six patients were tested for olfactory function
with The Pocket Smell Test or The Brief Smell Identifi-
cation Test – Sensonics, Inc. (Haddon Heights, NJ, USA)
and had a normal sense of smell.
FGFR1 functional studies
All the three FGFR1 variants were predicted to be patho-
genic by at least one of the three prediction programmes
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Figure 1
Functional analysis of FGFR1 variants. (A, B and C) Signalling activity of WT
and altered FGFR1 receptors in L6 myoblasts. Plotted are meansGS.E.M. of
three independent experiments. p.Ser107Leu (A) and p.Pro772Ser (B)
variants had normal signalling activity, while p.Arg448Trp had reduced
maximal signalling activity (**statistically significant (P!0.01)) (C).
(D) Western blot analysis of CHO cells transiently transfected with empty
vector (EV), FGFR1 WT or p.Arg448Trp constructs. UT, untreated; EH, EndoH
treated; PG, PNGase treated. (E and F) Densitometry analysis of total
protein and maturation levels of WT and p.Arg448Trp receptors. Plotted
are meansGS.E.M. of three independent experiments. (G) Cell-surface
expression levels of WT and p.Arg448Trp receptors assessed in live
transiently transfected COS-7 cells. Plotted are meansGS.E.M. of five
independent experiments (*statistically significant (P!0.05)).
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tested (Table 1). Signalling activity of these variants was
assessed in vitro using the well-established FGF-responsive
osteocalcin reporter system, which acts downstream of
the MAPK pathway. Cells expressing the p.Ser107Leu
and p.Pro772Ser variants elicited dose–response curves
similar to the WT FGFR1c curve (Fig. 1A and B).
The p.Arg448Trp variant, on the other hand, demon-
strated a small (approximately 15%) but significant
reduction in maximal signalling activity (P!0.01;
Fig. 1C). To evaluate potential molecular mechanisms
underlying the observed reduced signalling activity, we
performed protein expression studies. Overall protein
expression and maturation levels of p.Arg448Trp were
similar to those for the WT, indicative of normal protein
synthesis and folding processes (Fig. 1D, E and F). However,
cell-surface expression levels of this variant were signi-
ficantly increased compared with the WT (approximately
20%, P!0.05; Fig. 1G), indicating a defect in the receptor
internalization process.
Discussion
Congenital hypopituitarism (CH) is implicated in
considerable morbidity and leads to premature mortality
(18). Although many genetic causes have been discovered,
the majority of patients remain without genetic diagnosis
(19, 20, 21). In this study, due to the clinical and genetic
overlap between IHH/KS and CPHD, we investigated the
presence of deleterious variants of two genes classically
associated with IHH/KS in a large cohort of Brazilian
CPHD patients. We found four patients harbouring three
different FGFR1 variants (p.Ser107Leu, p.Arg448Trp and
p.Pro772Ser) and two patients with PROKR2 variants
(p.Arg85Cys and p.Arg248Glu).
Variants of FGFR1
The first detection of FGFR1 defects in CPHD patients, to
our knowledge, was the identification of a submicroscopic
deletion including the FGFR1 gene in a male patient. This
patient had GH, LH and FSH deficiencies associated with
anosmia and spherocytosis (22). Another submicroscopic
deletion involving FGFR1, identified during a study
analysing 69 Japanese patients with CPHD, was detected
in a female patient with CPHD associated with epilepsy,
learning disability and Chiari type 1 malformation (23). In
addition to the submicroscopic deletion, in this study, two
heterozygous missense variants (p.Val102Iso and
p.Ser107Leu) were also found in two unrelated patients.
These variants were present at a low frequency in the
Japanese control group. Results of functional studies of the
two variants revealed nearly normal transactivating
functions in luciferase assays (Table 3). The FGFR1 variant
p.Ser107Leu was also found in our cohort, in a patient
born to Japanese parents, as would be expected, we did not
find the variant in our Brazilian control group. The
functional study performed by us (Fig. 1) revealed no
difference in transactivation in comparison with the WT,
confirming the findings of the previous Japanese popu-
lation study (23). Taking into account the presence of the
variant in Japanese controls and population databases, an
unaffected first-degree relative carrying the variant, and
the in vitro data, it is unlikely that this variant
(p.Ser107Leu) alone is causing the phenotype.
Concerning the p.Pro772Ser variant, due to its finding
in five of the 400 healthy controls, a MAF of 4.2% in
African-based populations – one of the major ethnic
populations in Brazil – and the presence of an unaffected
mother that carries this variant, it is reasonable to
conclude that this is a polymorphism.
Table 3 Characteristics of FGFR1 missense variants found in patients with CPHD.
Variant
Signalling
activity Expression
Patients Controls
Referencesn Frequency (%) n Frequency (%)
p.Thr112Thr NS NS 103a 3 268 0 (3)
p.Ser450Phe k Z 0
p.Pro483Ser k Z 0
p.Val102Ile Y NS 69 3 100 2 (23)
p.Ser107Leu Z NS 1
p.Ser107Leu Z NS 156 2 400 0 Present study
p.Arg448Trp Y NS 0
p.Pro772Ser Z NS 1.25
NS, not studied; Z, similar to the WT.
aPatients with CPHD and/or SOD.
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The p.Arg448Trp variant, on the other hand, has not
been described to date in population databases, it shows a
reduced signalling activity, probably due to a defect in
receptor internalization process (Fig. 1), and is considered
deleterious according to three in silico prediction tools
(Table 1). Taking into account all this information
together, it is likely that this variant contributes to the
phenotype, although first-degree relatives are unaffected
carries. Also, the possibility of an oligogenic mechanism
similar to that seen in IHH/KS (17) cannot be discarded.
In an additional study focusing on the genetic overlap
in KS, CPHD and septo-optic dysplasia (SOD), a cohort of
103 patients was examined. Three heterozygous variants
(p.Thr112Thr, p.Ser450Phe and p.Pro483Ser) were found
in FGFR1 in three different unrelated patients with CPHD
and SOD. The latter two variants showed decreased
signalling activity in luciferase reporter assays and similar
overall expression and maturation levels in western
blotting analysis (3).
In summary, considering the present study and the
previously published data for the two other cohorts descri-
bed above (3, 23), to date, a total of 328 patients with CPHD
and/or SOD have been screened for FGFR1 mutations, and
nine patients (2.7%) were found to harbour eight different
heterozygous FGFR1 variants with variable probabilities of
having a significant role in the phenotype (Table 3).
Variants of PROKR2
PROKR2 mutations have been previously screened for in
patients with CH. Reynaud and colleagues screened 72
patients with pituitary stalk interruption syndrome (PSIS)
and found three heterozygous missense variants
(p.Leu173Arg, p.Arg85His and p.Ala51Thr). The first two
showed deleterious effects in functional studies supporting,
according to the authors, a causative role to the phenotype
(24). McCabe and colleagues (25) screened 422 patients with
CH, holoprosencephaly and/orSOD and foundfive missense
variants in 11 unrelated patients, three of them (p.Arg85Leu,
Leu173Arg and Arg268Cys) proved to be deleterious in
functional studies. In the latter study, the p.Leu173Arg
variant was inherited by the patient from his unaffected
mother, who was proven to be homozygous for the variant.
Thepoor genotype–phenotype correlation led the authors to
conclude that the contribution of PROKR2 variants to the
phenotype is uncertain (25).
The PROKR2 variants found in our cohort of 156
patients have not been previously described in CH, PSIS or
SOD, but have already been described in patients with
KS/IHH and have been submitted to functional studies
(16, 26, 27). The p.Arg85Cys variant showed modest but a
significant 30% reduction in maximal MAPK activation in
an Egr1-Luc assay (26). In inositol phosphatidyl (IP)
accumulation assays, the variant showed similar dose–
response curves to WT PROKR2. Also, the p.Arg85Cys
variant does not interfere with PROK2 ligand binding and
its plasma membrane expression is not reduced according
to the results of western blot analyses (26). Our patient
inherited the variant from an unaffected father.
The p.Arg248Glu variant is located within the last
intracellular loop, and results of functional analyses
revealed normal transcription activity in an Erg-Luc assay
but decreased calcium mobilization activity (72% of WT) in
an aequorin-based Ca2C flux assay. Its expression level was
similar to that of the WT PROKR2 in western blot
experiments (16). This variant does not have a MAF
described in population databases and the patient’s mother
is an unaffected carrier.
To date, including our cohort, 650 patients with
CPHD and/or SOD have been studied for PROKR2
mutations and 16 patients (2.5%) harbour eight different
heterozygous PROKR2 variants. Functional studies have
been performed on all variants and six of them were
proved to be at least partially deleterious.
In conclusion, FGFR1 and PROKR2 variants may
contribute to the phenotype of patients with CPHD but
are unlikely to be implicated in isolation. Consistently
with the results of previous studies, we believe that it is
likely that other associated genetic and/or environmental
factors are involved in the aetiology of this condition.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
EC-15-0015.
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